SCHEMBL990720

SCHEMBL990720

Oc1ccc(CCBr)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.69
MEN1 O00255 1/20 0.69
ESR1 P03372 4/20 0.68
ESR2 Q92731 2/20 0.68
CA2 P00918 1/20 0.59
ALDH1A1 P00352 3/20 0.56
ADRA2A P08913 3/20 0.56
SLC6A2 P23975 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HTR1A P08908 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTR3A P46098 1/20 0.56
BACE1 P56817 1/20 0.56
TAAR1 Q96RJ0 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TDP1 Q9NUW8 2/20 0.55
BLM P54132 1/20 0.54
LTA4H P09960 1/20 0.54
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2281085 0.85 TDP1 (0.71) KMT2AMEN1ESR1ESR2CA2
SCHEMBL1428981 0.84 ESR1 (0.62) KMT2AMEN1ESR1ESR2CA2
SCHEMBL6964959 0.82 ESR1 (0.59) KMT2AMEN1ESR1ESR2CA2
SCHEMBL69344 0.82 ESR1 (1.00) KMT2AMEN1ESR1ESR2CA2
SCHEMBL30932186 0.82 TDP1 (0.67) KMT2AMEN1ESR1ESR2CA2
SCHEMBL3873458 0.82 ESR1 (1.00) KMT2AMEN1ESR1ESR2CA2
SCHEMBL11557511 0.80 ESR1 (0.63) KMT2AMEN1ESR1ESR2CA2
SCHEMBL9143112 0.80 ESR1 (0.63) KMT2AMEN1ESR1ESR2CA2
SCHEMBL1171632 0.80 ESR1 (0.63) KMT2AMEN1ESR1ESR2CA2
SCHEMBL1172696 0.80 ESR1 (0.63) KMT2AMEN1ESR1ESR2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113398284-B Molecular probe for tumor targeted nuclide diagnosis and treatment, preparation method and application 江苏省原子医学研究所 2023-04-14 CN claimed
CN-113683491-A Preparation method of 4- (2-bromoethyl) phenol 王传良 2021-11-23 CN claimed
CN-113683522-A Preparation method of N-methyltyramine hydrochloride 广汉市派瑞林科技有限责任公司 2021-11-23 CN claimed
CN-113620821-A Preparation method of hordenine hydrochloride 广汉市派瑞林科技有限责任公司 2021-11-09 CN claimed
CN-113398284-A Molecular probe for tumor targeted nuclide diagnosis and treatment, preparation method and application 江苏省原子医学研究所 2021-09-17 CN claimed
CN-101190923-B Asymmetric bridged dinuclear metallocene compound, preparation thereof and application thereof in olefin polymerization PETROCHINA CO LTD 2010-11-03 CN claimed
CN-101190923-A Asymmetric bridged dinuclear metallocene compound, preparation thereof and application thereof in olefin polymerization CHINA PETROLEUM GAS CO LTD (CN) 2008-06-04 CN claimed
CN-101190930-A Dinuclear metallocene compound, preparation thereof and application thereof in olefin polymerization CHINA PETROLEUM GAS CO LTD (CN) 2008-06-04 CN claimed
US-20260132240-A1 LINEAR BLOCK COPOLYMER AND CURABLE THERMOSETTING COMPOSITION COMPRISING THE LINEAR BLOCK COPOLYMER SHPP GLOBAL TECH B V (NL) 2026-05-14 US disclosed
US-12623212-B2 Physically reinforced structured organic film (SOF) anion exchange membranes (AEMs) XEROX CORPORATION (US) 2026-05-12 US disclosed
EP-4702022-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE Halda Therapeutics Opco, Inc. (US) 2026-03-04 EP disclosed
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2026-01-29 US disclosed
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 US disclosed
US-20250304613-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH ALNYLAM PHARMACEUTICALS, INC. (US) 2025-10-02 US disclosed
US-3933897-A ANTIULCER, ASTHMA, RENAL DYSFUNCTION THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933895-A PROSTAGLANDINS, ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933900-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933898-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933899-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933896-A ANTICOAGULANTS, ASTHMA, LABOR INDUCERS, CERVICAL DILATION THE UPJOHN COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12623212-B2 Physically reinforced structured organic film (SOF) anion exchange membranes (AEMs) EPCAM, SGMS1, PEF1 KMT2A 4515/4885MEN1 4634/4885ESR1 674/4885
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS KMT2A 3832/4885MEN1 2321/4885ESR1 3527/4885
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer ADORA1, ADORA3, OPRL1 KMT2A 3358/4885MEN1 3935/4885ESR1 3954/4885
US-20250304613-A1 AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH AOC2, RTCB, AOC3 KMT2A 2172/4885MEN1 3651/4885ESR1 610/4885
US-20260132240-A1 LINEAR BLOCK COPOLYMER AND CURABLE THERMOSETTING COMPOSITION COMPRISING THE LINEAR BLOCK COPOLYMER CBLB, UBE4A, PSMD14 KMT2A 1729/4885MEN1 4470/4885ESR1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.